CIP
PCRX icon

Convergence Investment Partners’s Pacira BioSciences PCRX Stock Holding History

Convergence Investment Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,010
Closed -$174K – 343
2019
Q2 		$174K Buy
+4,010
New +$170K 0.04% 270
2015
Q3 		– Sell
-3,406
Closed -$241K – 393
2015
Q2 		$241K Sell
3,406
-5,534
-62% -$436K 0.02% 334
2015
Q1 		$794K Sell
8,940
-14,592
-62% -$1.48M 0.11% 283
2014
Q4 		$2.09M Buy
23,532
+3,417
+17% +$323K 0.28% 131
2014
Q3 		$1.95M Buy
+20,115
New +$1.96M 0.27% 143

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Convergence Investment Partners's PCRX Position: Q3 2019 in Review

Convergence Investment Partners sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 4,010 shares — an estimated $174K sold.

Convergence Investment Partners first reported a position in PCRX in Q3 2014 and held it in 5 quarters. The position peaked at $2.09M in Q4 2014. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

  • Convergence Investment Partners reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 4,010 Pacira BioSciences shares in Q3 2019, an estimated $174K.
  • Convergence Investment Partners first reported a position in Pacira BioSciences in Q3 2014 and held it in 5 quarters.
  • Convergence Investment Partners's Pacira BioSciences position peaked at $2.09M in Q4 2014.
  • 211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Convergence Investment Partners's 13F filing for Q3 2019, filed 22 Oct 2019.